CLINICAL STUDIES

Boston Scientific completes enrollment in heart failure trial

Written by Editorial Staff   
Friday, April 25, 2008

FURTHER READING

Section

PDF Print Email
Boston Scientific has completed the enrollment in its Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT).

The company said that the trial will include 1,820 patients and examine the benefits of Boston Scientific’s CRT-defibrillators (CRT-Ds) in a new population of heart failure patients, following in the tradition of MADIT, MADIT II and COMPANION, according to the company.

MADIT-CRT is designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors and in those with other forms of impaired heart function, the Natick, Mass.-based company said. Boston Scientific hopes the trial will demonstrate if earlier intervention with CRT-D therapy can slow a patient's progression from early-stage heart failure to late-stage heart failure (Class III and IV).
Last Updated ( Friday, April 25, 2008 )